Skip to content

Medical Affairs

Intelligence Hub

Overview

Home
My Work
Command Center

Plan & execute

Medical Plans
Launch Readiness
Budget & Resources
Risks & Decisions

Field & science

Engagements
Insights
Evidence Generation

Communicate

Publications
Congresses
Medical Information

Govern

Reports
Data Quality
Administration

Helixor Therapeutics

Sample data · FY2026

Scope·4 products·FY2026

HODr. Helen OkaforGlobal Head of Medical Affairs

EngagementsENG-0098

Medical education · Dr. Ulrich Abbott

23 Apr 2026 · In person · Dr. Ulrich Abbott, Hôpital Pitié-Salpêtrière · MSL James Whitfield · Vantrexa

ReviewedVeeva CRMENG-0098MI request

Capture insight from this engagement

Location: Hôpital Pitié-Salpêtrière
Therapeutic area: Oncology
Country: France
Stakeholder tier: Tier 1
Strategic objective: Not linked
Initiative: Not linked
MSL: JWJames WhitfieldSenior MSL, Oncology (US East)
Product: Vantrexa (vantrelimab)

Topics discussed

Duration of response

Scientific content used

VTX core scientific deck v3.2
VOYAGE-1 pivotal data summary

Questions raised

What is the evidence for re-challenge with checkpoint inhibitors after progression on vantrelimab?
What was the median PD-L1 testing turnaround in the pivotal trial sites?

Notes

Medical education with pathologist at Hôpital Pitié-Salpêtrière. Discussed duration of response.

Insights captured (1)

Capture insight

INS-0048Medium
Duration of response
Duration of response: gap in current materials reported by pathologist (FR).
Closed

Review workflow

Draft
Submitted
3Reviewed

Review complete. Quality ratings and insights can now be used in aggregates.

Follow-ups

No follow-ups recorded.

Quality ratings

1–5, rated at review

Scientific relevance: 5
Strategic relevance: 2
Depth of exchange: 5
Actionability: 4

Data lineage

Source system: Veeva CRM
Sync: Veeva CRM · synced 2026-09-15 08:00 UTC
System of record: Veeva CRM
Record id: ENG-0098

Audit history (0)

All create, update and approval events for this record

No audit events in sample data